Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
C. McKerr (Bristol, United Kingdom), A. Massey (Bristol, United Kingdom), G. Lynch (Bristol, United Kingdom), N. Jarad (Bristol, United Kingdom). Factors associated with the need of intravenous antibiotics in a cohort of adult patients with non-CF bronchiectasis. 2679

Member's Comments

No comment yet.

Related content which might interest you: Home intravenous antibiotic treatments in cystic fibrosis adult patients Source: Eur Respir J 2002; 20: Suppl. 38, 158s Year: 2002 Time to diagnosis and adherence to guidelines in a large cohort of patients with non-CF bronchiectasis Source: Annual Congress 2010 - Bronchiectasis and respiratory infections caused by Pseudomonas Year: 2010 Prognostic indicators of adult patients with non-CF bronchiectasis and those with combined COPD and non-CF bronchiectasis Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis Year: 2018 The use of home intravenous antibiotics in adult non-CF bronchiectasis Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation Year: 2015 Immunomodulative therapy in young patients with non-CF bronchiectases exacerbations Source: Annual Congress 2009 - Bacterial infections of upper and lower respiratory tract in childhood Year: 2009 Inhaled colistin in elderly patients with bronchiectasis and chronic bronchial infection with pseudomonas Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012 Comparing pneumonia incidence in COPD patients treated with or without inhaled corticosteroid Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data Year: 2021 Factors associated with exacerbations in US patients with COPD Source: Annual Congress 2009 - Exacerbations and characteristics of COPD Year: 2009 Factors associated with one-year mortality in hospitalized patients with exacerbation of bronchiectasis. Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria Year: 2020 Antibiotic treatment strategies in adults with bronchiectasis Source: Eur Respir Mon 2011; 52: 211-222 Year: 2011 Characteristics of COPD patients treated with inhaled corticosteroid in primary care Source: International Congress 2018 – Biomarkers for evaluating COPD Year: 2018 Impact of inhaled corticosteroid use on outcome in COPD patients hospitalised with pneumonia Source: Annual Congress 2010 - Aetiology and outcomes of infective exacerbations of COPD Year: 2010 Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia Source: Eur Respir J 2011; 37: 36-41 Year: 2011 Demographics and characteristics of antibiotic use in non-cystic fibrosis bronchiectasis patients Source: International Congress 2016 – From pleura to bronchi: new insights Year: 2016 Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation Source: Eur Respir J, 56 (5) 2001875; 10.1183/13993003.01875-2020 Year: 2020 Out-patient combination therapy with inhaled corticosteroids and bronchodilators is associated with lower in-hospital mortality in pneumonia in patient with COPD Source: International Congress 2016 – Prevalence, prognosis, and risk factors of COPD Year: 2016 Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia Source: Eur Respir J 2010; 36: 751-757 Year: 2010 The clinical impact of nebulised antibiotics in adults with bronchiectasis and chronic pseudomonas aeruginosa Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020 Effects of long-term azithromycin treatment in patients with non-cystic fibrosis stable bronchiectasis Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007 Oral antibiotics vs placebo for exacerbations of paediatric bronchiectasis Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Intensive care and infection Year: 2019